Hello 🙋🏻♂️ to the community,
I don't want to beat around the bush. As you've surely noticed, my portfolio has become one position lighter due to the sudden sale of $ROR (+0 %) has lost one position. With that in mind, I’d like to introduce you today to a company that could be a potential replacement for me.
☢️ Mirion Technologies: The Legally Mandated Toll Booth of Nuclear and Cancer Medicine
In the shadow of the global energy and medical infrastructure, a very different megatrend is gaining momentum: the renaissance of nuclear power and the boom in radiopharmaceutical cancer therapy. Right in the middle of it all sits an unnoticed, highly specialized monopoly:
Mirion Technologies $MIR (+3,26 %) . The company doesn’t build reactors or cancer drugs—it builds the indispensable nervous system for monitoring them. Anyone who needs to measure, control, or shield against radiation can’t do without Mirion.
Through its recent, strategically highly attractive acquisitions of Paragon and Certrec, Mirion has transformed itself from a pure measurement device manufacturer into a highly sticky software, service, and compliance platform for critical facilities. The stock reflects the operational turnaround following the complex SPAC listing phase: In July 2026, after a strong recovery, the stock is trading at around $17.00 (market capitalization ~$4.18 billion). The market is beginning to realize that Mirion controls the legally mandated “toll booth” for the security of the physical-nuclear world.
1. The Business Model: Regulatory Mandates as an Endless Cash Generator ⚙️🏢🏥
Mirion operates in a B2B environment that is almost completely decoupled from the traditional investment cycle. No one buys Mirion products for lifestyle reasons—they buy them because lawmakers mandate it under threat of draconian penalties.
① The Toll Booth Principle (Hardware + Recurring Service): Mirion $MIR (+3,26 %) installs sophisticated radiation detectors, dosimetry systems, and monitoring sensors in nuclear power plants, military bases, and hospitals. Once installed, the real business begins: legal calibration requirements, software updates for data analysis, and the continuous evaluation of dosimeter badges (which medical staff must wear on their bodies) ensure a steady stream of recurring revenue.
② The Paragon & Certrec Flywheel (Compliance Lock-In): With its most recent acquisitions, Mirion has gained deep access to the operational software and licensing management of nuclear facilities. Certrec controls critical compliance SaaS tools for nuclear regulation. Companies listed here effectively never switch providers again for security and certification reasons.
③ Scaling Amid Nuclear Growth: While the production of high-end sensors yields solid margins, profitability in the service and software sectors is skyrocketing. Organic order volume surged by a phenomenal +42% in Q1 2026 (including M&A), securing a massive pipeline for the coming years.
2. The Technology: Why Nuclear and Medical “Edge” Is Untouchable 🧪⚡
Mirion’s technological promise is absolute, error-free precision in extreme environments. If a sensor in cancer therapy displays the wrong dose or fails in a reactor’s cooling loop, the system collapses.
The regulatory safety moat: Every Mirion system $MIR (+3,26 %) must be certified by regulatory agencies such as the U.S. Nuclear Regulatory Commission (NRC). These processes take years and cost millions. A potential low-cost competitor from overseas would fail right at the bureaucratic and technological hurdle of initial approval.
The Medical Cloud Platform (Sun Nuclear): In the Mirion Medical segment, the company uses its software to standardize quality assurance in radiation therapy. Oncology clinics control their complex linear accelerators using Mirion software—an extremely sticky ecosystem that scales directly with demographic change and new cancer treatments (radiopharmaceuticals).
The SMR and Next-Gen Operating System: Mirion $MIR (+3,26 %) provides the sensor technology for the new Small Modular Reactors (SMRs). Since these reactors operate in a more digital and decentralized manner than older reactors, the software and sensor density per megawatt is significantly higher.
3. Key Figures (as of July 2026 / Q1 FY26) 📊
Stock Exchange Listing: Listed on the NYSE under the ticker MIR.
Market Capitalization: ~$4.18 billion.
Revenue & Momentum: In the most recent reported quarter (Q1 2026), revenue skyrocketed by a staggering 27.5% year-over-year to $257.6 million (driven by strong organic demand and M&A consolidation).
🚀Order Surge (Backlog): Orders rose by 19% (organically) or 42% including M&A in the first quarter to 288 million USD—a new record that far exceeds current revenue (book-to-bill ratio significantly greater than 1).
🚀Strong Margin Performance: The adjusted gross margin remains stable at a robust 45.8%. Adjusted EBITDA climbed to $54.3 million in Q1 (adjusted EBITDA margin at a comfortable 21.1%).
🚀The financial fortress (deleveraging): The deleveraging target is set: Management is focused on using strong free cash flow to sustainably push the leverage ratio (net debt / adj. EBITDA)—which was temporarily increased by M&A—below the critical comfort threshold of 3.0x by year-end.
🚀 Capital Efficiency (ROIC): With a historical ROIC of 1–2% (including massive M&A goodwill), Mirion is not, on paper, a classic, highly efficient compounder. Anyone investing here is making a deliberate bet that the Paragon and Certrec synergies will gradually drive up the real return on capital over the next few years.
🚀 Valuation: The adjusted forward P/E ratio for the full year 2026 is approximately 26x–28x (expected adjusted EPS of ~$0.60–0.65). Traditional GAAP earnings still show a slight loss due to M&A amortization (-$3.4M in Q1), which makes the stock appear artificially expensive when viewed through superficial filters.
4. Why is the stock particularly exciting right now? 🚀
1. The nuclear supercycle is becoming a reality
Whether it’s artificial intelligence in data centers or the decarbonization of industry, the demand for baseload electricity is leading to operating life extensions for existing nuclear power plants and massive new construction programs worldwide. Mirion $MIR (+3,26 %) earns revenue from every single one of these projects—without bearing the operational risk of a power plant operator.
2. The radiopharmaceutical boom in medicine
Medicine is undergoing a revolution driven by targeted alpha and beta therapies for cancer. These highly radioactive drugs must be monitored with extreme precision at every stage of logistics and administration. Mirion’s medical division is growing at a double-digit rate here as an indispensable supplier.
3. The End of SPAC Discounts
Wall Street hates opaque SPAC balance sheets with high debt levels. Since Mirion has now demonstrated in 2026 that its leverage ratio can be sustainably kept below 3x through strong free cash flow, the stock is undergoing an ongoing revaluation.
5. Competition & Moat ♟️
The landscape:
The niche specialists (Thermo Fisher $TMO (-1,27 %) , Canberra/Areva history): Major laboratory equipment suppliers often have small divisions for radiation measurement but rarely offer the fully integrated depth of software, calibration, compliance management, and dosimetry from a single source.
Local Players: Often too small to compete in global tenders for major military contracts or multinational hospital chains.
Mirion’s Moat in Bullet Points:
Extreme switching costs: Once a hospital or nuclear power plant has implemented Sun Nuclear’s or Certrec’s software platforms into its daily safety workflows, switching is practically impossible. The recertification costs and regulatory risk are disproportionate to any potential savings.
Legally Guaranteed Revenue: Even if the global economy slips into a deep recession, no operator can cut its spending on radiation protection and dosimetry monitoring. Revenue is defensively locked in.
6. Additional Insider Facts (The “Deep Dive” Bonus) 💡
The AI Compliance Lever: Mirion $MIR (+3,26 %) is rolling out automated AI tools as part of the Certrec integration; these tools scan regulatory changes issued by authorities in real time and automatically update nuclear power plant operating manuals. This transforms the traditional consulting business into high-margin software revenue.
The Defense Catalyst: Due to the changing geopolitical landscape, NATO countries are modernizing their nuclear early-warning systems and NBC protection equipment (civil defense, military) at a record pace. Mirion $MIR (+3,26 %) is the primary supplier of mobile and stationary detection systems in this sector.
7. Risks ⚠️
❗️The M&A integration risk: Paragon and Certrec were expensive acquisitions. Synergies must be fully realized at the margin level in the second half of 2026; otherwise, adjusted EBITDA could be negatively impacted.
❗️Delays in new reactor construction: Major nuclear projects (especially in Europe🇪🇺 and the U.S. 🇺🇸) are notorious for years-long delays. If the construction of large reactors is delayed, Mirion’s hardware revenue will also be pushed into the future.
❗️Political volatility: A sudden shift in sentiment toward nuclear power in key markets (e.g., following political shifts) could dampen long-term growth sentiment.
Earnings Preview (Q2 2026 – July 29, after U.S. market close)
The consensus: Expected ~$269.6 million in revenue (+21.0% YoY, driven largely by inorganic M&A effects) and adjusted (non-GAAP) EPS of ~$0.10–0.11.
What matters:
1. Genuine growth momentum: Will the organic revenue growth (excluding the acquisitions of Paragon/Certrec) once again reach a strong level (over 6–7%), and does order growth (Order Growth) pick up by 15–20%, as forecast by management?
2. Profitability & Dilution: Will the integration of the acquisitions and the high level of stock-based compensation (Stock-Based Compensation) weigh on the adjusted EBITDA margin, and will adjusted EPS stabilize after the weak first quarter?
3. Debt Reduction & Cash Flow Conversion: To what extent is the high net debt of ~$1.2 billion weighing on interest expense, and does the quarter provide the first concrete evidence that Mirion is on track to meet its full-year free cash flow guidance (USD 155–175 million) to rapidly reduce leverage?
My personal conclusion & Reaper Bonus 🧐
Mirion Technologies $MIR (+3,26 %) will deliver exactly what savvy value and infrastructure investors are looking for in 2026: a crisis-proof, regulatory-protected tolling business with strong organic momentum and an exploding order book. The transformation toward higher-value software and compliance revenues is underway. With the successful reduction of debt, the biggest risk is eliminated.
But if the integration of the new platforms is delayed, the costs of highly specialized engineers in the medical sector unexpectedly squeeze the operating margin, and at the same time Wall Street loses interest in the nuclear sector, the stock will quickly correct further. Without a flashy AI narrative, the mid-cap market won’t forgive margin-squeezing measures.
Jack’s Verdict:
“Mirion is the ultimate ‘boring business’ that you just want to leave sitting in your portfolio. Everyone’s looking at the tech giants that consume the electricity—but no one’s looking at the guys who make sure that energy source doesn’t blow up in our faces. A gross margin of over 45% on physical safety components shows that Mirion can dictate prices.”
REAPER RATING: 🟢 HOLD / WATCH
REAPER SCORE: 7.9 / 10 ·
@Get_Rich_Or_Die_Tryin @Tenbagger2024
@Raketentoni
@Stocktective
@Multibagger
@Dividendenopi
@schlimmschlimm and, of course, everyone else ✌️
